Metagenomi Therapeutics (MGX) Current Leases (2023 - 2026)
Metagenomi Therapeutics (MGX) posted quarterly Current Leases of $6.1 million for Q1 2026, up 8.96% year-over-year from $5.6 million in Q1 2025, and up 1.33% quarter-over-quarter from $6.0 million in Q4 2025.
Metagenomi Therapeutics (MGX) Current Leases (2023 - 2026) Analysis & Trends
Metagenomi Therapeutics (MGX) has reported Current Leases for 4 consecutive years, with $6.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Leases rose 8.96% year-over-year to $6.1 million; the TTM figure through Mar 2026 stood at $6.1 million (up 8.96% YoY), while the FY2025 annual figure was $6.0 million, up 7.74% from the prior year.
- Current Leases advanced to $6.1 million in Q1 2026 per MGX's latest filing, from $6.0 million in the prior quarter.
- Across five years, Current Leases topped out at $6.1 million in Q1 2026 and bottomed at $3.4 million in Q4 2023.
- Historically, Current Leases has averaged $5.2 million across 4 years, with a median of $5.5 million in 2025.
- Annual changes were most pronounced in 2024 — Current Leases soared 63.17% — and 2025, when it gained 2.08%.
- Metagenomi Therapeutics' Current Leases stood at $3.4 million in 2023, then jumped by 63.17% to $5.6 million in 2024, then grew by 7.74% to $6.0 million in 2025, then advanced by 1.33% to $6.1 million in 2026.
- Business Quant data shows MGX's Current Leases at $6.1 million in Q1 2026, $6.0 million in Q4 2025, and $5.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Metagenomi Therapeutics | 46.51 Mn | 46.51 Mn | - | 6.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.24 Mn |
| Mar 31, 2026 | 6.11 Mn |
| Dec 31, 2025 | 6.03 Mn |
| Sep 30, 2025 | 5.57 Mn |
| Jun 30, 2025 | 5.51 Mn |
| Mar 31, 2025 | 5.60 Mn |
| Dec 31, 2024 | 5.59 Mn |
| Sep 30, 2024 | 4.70 Mn |
| Jun 30, 2024 | 5.40 Mn |
| Mar 31, 2024 | 4.38 Mn |
| Dec 31, 2023 | 3.43 Mn |